Medicenna Therapeutics Corp (TO:MDNA) — Market Cap & Net Worth
Market Cap & Net Worth: Medicenna Therapeutics Corp (MDNA)
Medicenna Therapeutics Corp (TO:MDNA) has a market capitalization of $36.81 Million (CA$50.88 Million) as of May 2, 2026. Listed on the TO stock exchange, this Canada-based company holds position #22994 globally and #843 in its home market, demonstrating a 7.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medicenna Therapeutics Corp's stock price CA$0.61 by its total outstanding shares 83411435 (83.41 Million). Analyse MDNA cash generation efficiency to see how efficiently the company converts income to cash.
Medicenna Therapeutics Corp Market Cap History: 2015 to 2026
Medicenna Therapeutics Corp's market capitalization history from 2015 to 2026. Data shows growth from $3.92 Million to $36.81 Million (22.82% CAGR).
Medicenna Therapeutics Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medicenna Therapeutics Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MDNA by Market Capitalization
Companies near Medicenna Therapeutics Corp in the global market cap rankings as of May 2, 2026.
Key companies related to Medicenna Therapeutics Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Medicenna Therapeutics Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Medicenna Therapeutics Corp's market cap moved from $3.92 Million to $ 36.81 Million, with a yearly change of 22.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$36.81 Million | -33.70% |
| 2025 | CA$55.51 Million | -44.24% |
| 2024 | CA$99.56 Million | +292.86% |
| 2023 | CA$25.34 Million | -34.38% |
| 2022 | CA$38.62 Million | -69.52% |
| 2021 | CA$126.71 Million | -64.71% |
| 2020 | CA$359.01 Million | +75.00% |
| 2019 | CA$205.15 Million | +385.71% |
| 2018 | CA$42.24 Million | -65.00% |
| 2017 | CA$120.68 Million | +1900.00% |
| 2016 | CA$6.03 Million | +53.85% |
| 2015 | CA$3.92 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Medicenna Therapeutics Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.81 Million USD |
| MoneyControl | $36.81 Million USD |
| MarketWatch | $36.81 Million USD |
| marketcap.company | $36.81 Million USD |
| Reuters | $36.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more